Yarrow Bioscience, Inc.

YARW

Yarrow Bioscience, Inc.

YARW

Insider Sentiment (TTM):

Last Purchase:2025-01-15Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:12,714,479Shares Outstanding:42,768,000Institutional Ownership Pct.:29.73%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	23	25	24	22	28	20	16	30	19	31	15
Marketable Securities Current	0	0	5	18	22	42	54	48	67	63	-
Restricted Cash And Cash Equivalents At Carrying V…	-	-	-	-	-	0	0	0	0	0	0
Accounts Receivable Net Current	-	-	-	-	-	-	-	-	-	-	0
Prepaid Expense And Other Assets Current	1	1	1	5	5	3	3	6	4	3	2
Assets Current	24	26	30	44	55	64	74	84	90	96	18
Assets Noncurrent
Property Plant And Equipment Net	0	0	0	0	0	0	-	-	-	0	-
Operating Lease Right Of Use Asset	-	-	0	0	0	0	0	0	0	0	-
Prepaid Expense And Other Assets Noncurrent	0	0	0	0	1	2	3	3	1	-	2
Prepaid Expense Noncurrent	-	-	-	-	-	2	-	-	-	2	-
Assets Noncurrent	0	0	0	0	2	2	3	3	1	2	-
Assets	24	26	30	45	56	67	76	87	92	98	19
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Trade Current	1	0	1	1	4	3	4	5	3	2	1
Accrued Liabilities Current	1	1	1	4	7	9	6	5	4	4	4
Employee Related Liabilities Current	0	0	0	1	1	1	1	1	0	2	1
Supplemental Unemployment Benefits Severance Benef…	-	-	-	-	-	-	-	-	-	0	0
Operating Lease Liability Current	-	-	0	0	0	0	0	0	0	0	-
Other Liabilities Current	-	-	0	0	1	1	1	1	-	0	-
Liabilities Current	2	1	2	6	12	15	13	12	7	8	6
Liabilities	2	1	2	6	12	15	13	12	8	9	8
Liabilities Noncurrent
Stockholders Equity
Temporary Equity
Operating Lease Liability Noncurrent	-	-	-	-	-	0	0	0	0	0	-
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	-
Temporary Equity Carrying Amount Including Portion…	-	-	-	-	-	-	-	-	-	0	0
Other Liabilities	-	-	-	-	-	0	0	0	1	1	1
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0
Liabilities Noncurrent	-	-	-	-	-	0	0	0	1	1	-
Additional Paid In Capital	786	786	785	784	784	783	783	782	781	780	697
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	-0	0	0	0	-0	-0	0	-
Retained Earnings Accumulated Deficit	-764	-761	-758	-746	-740	-731	-719	-707	-698	-691	-685
Stockholders Equity	22	25	28	39	44	52	64	75	83	89	12
Liabilities And Stockholders Equity	24	26	30	45	56	67	76	87	92	98	19
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Shares Authorized	20	20	20	20	20	20	20	20	20	20	-
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	-
Series A Preferred Stock	-	-	-	-	-	-	-	-	-	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	-
Temporary Equity Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Shares Authorized	-	-	-	-	-	-	-	-	-	20	20
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	1	1	1	0	0	0	0	0	0	0	0
Temporary Equity Shares Outstanding	-	-	-	-	-	-	-	-	-	0	0
Shares Outstanding	1	1	1	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-2.07%	1.48%	-	-	-	-	-	-	-	-	-	-
2025	-26.92%	9.23%	12.31%	-14.57%	6.29%	1.71%	-	-	-	4.93%	1.62%	11.59%
2024	-4.15%	-25.66%	-21.13%	9.83%	9.25%	53.18%	-6.18%	0.48%	-12.52%	-27.04%	-38.63%	-55.36%
2023	-	-	-	-31.11%	-40.93%	-49.58%	-14.08%	-37.93%	-45.40%	9.01%	1.35%	24.77%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	15.26	20.86	12.53	7.60	4.47	4.35	5.81	7.13	13.02	12.73	2.72
Quick Ratio	14.87	20.17	12.11	6.79	4.09	4.15	5.55	6.65	12.41	12.38	2.44
Working Capital	21.98M	24.55M	27.62M	38.51M	42.62M	49.62M	60.87M	72.02M	83.29M	88.43M	11.06M
Leverage & Debt
Debt to Equity	0.07	0.05	0.09	0.15	0.28	0.28	0.20	0.16	0.10	0.10	0.67
Debt Ratio	0.07	0.05	0.08	0.13	0.22	0.22	0.17	0.14	0.09	0.09	0.40
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Days Sales Outstanding TTM	-	-	-	-	-	-	-	-	-	-	371.70
Receivables Turnover TTM	-	-	-	-	-	-	-	-	-	-	0.98
Per Share Metrics
Diluted EPS TTM	-14.39	-20.99	-30.85	-45.08	-49.44	-46.77	-39.92	-33.38	-34.15	-138.48	-490.69
Free Cash Flow Per Share TTM	-1.55	-17.40	-23.15	-33.11	-43.88	-39.88	-35.35	-31.41	-32.70	-123.34	-381.09
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-5,738.10%	-5,757.70%	-8,312.39%	-8,949.58%	-7,513.06%	-8,709.98%	-7,646.65%	-6,345.88%	-7,272.58%	-6,900.47%	-8,590.68%
Net Profit Margin TTM	-4,899.60%	-5,028.29%	-7,433.24%	-8,097.69%	-6,974.55%	-7,950.90%	-6,896.55%	-5,849.18%	-6,874.47%	-6,710.38%	-9,098.59%
Growth Metrics
Net Revenue Growth (1Y)	-58.35%	-28.74%	-27.99%	-2.06%	43.03%	18.16%	39.27%	19.41%	6.28%	-11.11%	-52.42%
Net Income Growth (1Y)	-70.74%	-54.94%	-22.39%	35.59%	45.11%	40.00%	5.56%	-18.97%	-13.20%	22.59%	29.69%
EPS Growth (1Y)	-70.89%	-55.12%	-22.72%	35.07%	44.80%	-66.23%	-91.86%	-93.77%	-93.36%	-61.98%	27.16%
Valuation Metrics
P/E TTM	-1.28	-0.80	-0.53	-1.03	-0.90	-2.02	-1.33	-1.67	-2.54	-0.47	-0.23
P/B TTM	0.71	0.59	0.50	1.02	0.86	1.55	0.71	0.63	0.89	0.15	0.65
P/S TTM	62.56	40.44	39.44	83.65	62.91	160.75	91.67	97.44	174.44	31.87	21.14
Market Cap	15.76M	14.44M	14.00M	39.82M	38.06M	80.53M	45.19M	47.36M	73.79M	13.51M	7.48M
Enterprise Value	-7.16M	-10.19M	-10.03M	17.77M	9.85M	60.61M	28.87M	17.70M	54.67M	-17.11M	-8.02M
Calculated Values
Free Cash Flow TTM	-1.33M	-14.88M	-19.80M	-28.31M	-37.45M	-33.97M	-30.11M	-26.75M	-27.84M	-25.34M	-25.02M
Net Debt	-22.93M	-24.63M	-24.03M	-22.05M	-28.21M	-19.93M	-16.32M	-29.66M	-19.12M	-30.62M	-15.50M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-01-15Purchase

Owner: Lepore, Patrick G

Title: -

Shares: 15,000

Price/Share: $2.92

Value: $43,800.00

Shares Owned: 51,472

Relationship: Director

Ownership: Direct

2023-11-15Purchase

Owner: Lepore, Patrick G

Title: -

Shares: 13,000

Price/Share: $3.91

Value: $50,830.00

Shares Owned: 36,472

Relationship: Director

Ownership: Direct

2023-03-20Purchase

Owner: Harsch, Mutya

Title: Chief Legal Officer and GC

Shares: 10,000

Price/Share: $2.50

Value: $25,000.00

Shares Owned: 22,721

Relationship: Officer

Ownership: Direct

2023-03-20Purchase

Owner: Lepore, Patrick G

Title: -

Shares: 20,000

Price/Share: $2.48

Value: $49,600.00

Shares Owned: 23,472

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-01-15	Lepore, Patrick G	Director	-	Direct	Purchase	15,000	2.92	$43,800.00	51,472	4
2023-11-15	Lepore, Patrick G	Director	-	Direct	Purchase	13,000	3.91	$50,830.00	36,472	4
2023-03-20	Harsch, Mutya	Officer	Chief Legal Officer and GC	Direct	Purchase	10,000	2.50	$25,000.00	22,721	4
2023-03-20	Lepore, Patrick G	Director	-	Direct	Purchase	20,000	2.48	$49,600.00	23,472	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

29.73%

Inst. Shares: 12,714,479

Shares Outstanding: 42,768,000

2025-12-31

17.39%

Inst. Shares: 7,436,533

Shares Outstanding: 42,768,000

2025-09-30

8.01%

Inst. Shares: 3,423,868

Shares Outstanding: 42,768,000

2025-06-30

18.60%

Inst. Shares: 7,951,796

Shares Outstanding: 42,759,000

2025-03-31

16.51%

Inst. Shares: 7,045,391

Shares Outstanding: 42,673,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	12,714,479	42,768,000	29.73%
2025-12-31	7,436,533	42,768,000	17.39%
2025-09-30	3,423,868	42,768,000	8.01%
2025-06-30	7,951,796	42,759,000	18.60%
2025-03-31	7,045,391	42,673,000	16.51%
2024-12-31	7,008,104	42,589,000	16.46%
2024-09-30	7,292,885	42,587,000	17.12%
2024-06-30	7,940,896	42,586,000	18.65%
2024-03-31	7,701,702	42,581,000	18.09%
2023-12-31	7,806,430	10,273,000	75.99%
2023-09-30	333,108	3,282,000	10.15%
2023-06-30	338,879	3,274,000	10.35%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Yarrow Bioscience, Inc. (YARW) — SEC Financial Statements & Analysis

Yarrow Bioscience, Inc. (YARW) is a pharmaceutical preparations company, incorporated in DE. Yarrow Bioscience, Inc. trades on Nasdaq as: YARW, VYNE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Yarrow Bioscience, Inc. reported a -58.35% year-over-year revenue growth, a Debt-to-Equity ratio of 0.07x, a Price-to-Sales (P/S) ratio of 62.56x (TTM), a Price-to-Book (P/B) ratio of 0.71x (TTM), at a market cap of $15.76M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -58.35%
Debt To Equity: 0.07x
P/S TTM: 62.56x
P/B TTM: 0.71x
Market Cap: $15.76M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Yarrow Bioscience, Inc. in?

Yarrow Bioscience, Inc. (YARW) operates in the Pharmaceutical Preparations industry.

What is YARW's market cap?

Yarrow Bioscience, Inc. (YARW) has a market capitalization of $15.76M as of 2026-06-30.

What exchange does YARW trade on?

Yarrow Bioscience, Inc. (YARW) trades on the Nasdaq.

Where is Yarrow Bioscience, Inc. incorporated?

Yarrow Bioscience, Inc. is incorporated in DE.